Anti-Inflammatory Drugs as Antivenom?

Compounds typically used to calm the immune system can prevent death from scorpion venom in mice, researchers report.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, CLINTON & CHARLES ROBERTSONAntidotes to scorpion venom may have been lurking under our noses for quite a while. Researchers in Brazil have found that they could keep mice stung by scorpions from succumbing to the toxic effects of the venom by administering the anti-inflammatory drugs indomethacin or celecoxib. The team, led by investigators at the University of São Paulo, published its results yesterday (February 23) in Nature Communications.

The team administered either indomethacin or celecoxib to mice dosed with scorpion venom, finding that both anti-inflammatory drugs protected against death. If the drugs have the same effects in humans, they could become regular fixtures of first-aid kits, obviating the need for expensive, more-volatile, and less-widely applicable antibody-based antivenoms. “The possibility for a generic treatment is exciting,” Yale University immunologist Noah Palm, who was not involved in the work, told Chemical & Engineering News.

The anti-inflammatory drugs apparently blocked prostaglandin E2, a lipid signaling molecule that causes lung edema and inflammation in animals stung by scorpions. This saved the mice from the deadly effects of the toxin. Lucia Faccioli of the University of São Paulo told Chemical & Engineering News that her team next plans ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies